Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients
Fig 2
Representative SRM chromatograms.
(A): blank DBS sample; (B): blank DBS sample with IS added; (C): S/N of IMA and norIMA at the LLOQ (50 and 10 ng/mL, respectively); (D): extracted DBS sample of a treated patient showing IS, IMA (575 ng/mL) and norIMA (94.3 ng/mL).